Treament of Rumination
Primary Purpose
Rumination Disorders
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Biofeedback
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Rumination Disorders
Eligibility Criteria
Inclusion Criteria:
- Rumination syndrome
Exclusion Criteria:
- Relevant organic diseases
Sites / Locations
- Vall d'Hebron Research Institute
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Biofeedback
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Number of rumination events after a challenge meal measured by electromyography
Rumination events will be identified by recording the activity of the thoraco abdominal muscles (intercostals, external oblique, internal oblique, upper rectus, lower rectus) by electromyography after a challenge meal. The response to the meal will be measured before and after treatment.
Secondary Outcome Measures
Number of self perceived rumination events.
Number of rumination events measured by questionnaires administered daily for 10 days before and after treatment.
Abdominal discomfort.
Abdominal discomfort will be measured by scales graded from 0 (no discomfort) to 10 (severe discomfort) administered daily for 10 days before and after treatment.
Number of self perceived rumination events up to 6 months.
Number of self perceived rumination events measured daily for 10 days using questionnaires at 1 month, 3 months and 6 months after treatment.
Full Information
NCT ID
NCT04167371
First Posted
November 15, 2019
Last Updated
February 11, 2022
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT04167371
Brief Title
Treament of Rumination
Official Title
Treament of Rumination
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
December 2, 2019 (Actual)
Primary Completion Date
October 30, 2020 (Actual)
Study Completion Date
February 1, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital Universitari Vall d'Hebron Research Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Background. Rumination syndrome is characterized by effortless recurrent regurgitation of recently ingested food into the mouth, with consequent expulsion or re-chewing and swallowing. In a previous study we showed that rumination is produced by an unperceived, somatic response to food ingestion. We developed an original biofeedback technique based on electromyography-guided control of abdominothoracic muscular activity. In a randomized, placebo-controlled trial we demonstrated the superiority of biofeedback over placebo for the treatment of rumination. However, the technique is technically complex and unpractical.
Aim. To prove the efficacy of a simplified biofeedback technique for the treatment of rumination. Selection criteria. Rumination after meal ingestion. Intervention. Patients will be randomized into biofeedback in placebo groups. Three sessions of either biofeedback or placebo intervention will be performed after ingestion of a probe meal during the first 3 weeks of the 4 weeks intervention period.
Biofeedback: patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
Placebo: abdominal and thoracic perimeter will be recorded but not shown to the patient and a pill of placebo containing 0.5 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
Primary Outcome Measure:
Number of rumination events measured by electromyography in response to the challenge meal before and after treatment.
Secondary Outcome Measures:
Number of self perceived rumination events measured by questionnaires administered daily for 10 days will before and after treatment.
Associated abdominal symptom measured by questionnaires administered daily for 10 days before and after treatment.
Follow up: number of self perceived rumination events measured at 1, 3 and 6 months after treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rumination Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Biofeedback
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Behavioral
Intervention Name(s)
Biofeedback
Intervention Description
Three sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Three sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
Primary Outcome Measure Information:
Title
Number of rumination events after a challenge meal measured by electromyography
Description
Rumination events will be identified by recording the activity of the thoraco abdominal muscles (intercostals, external oblique, internal oblique, upper rectus, lower rectus) by electromyography after a challenge meal. The response to the meal will be measured before and after treatment.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Number of self perceived rumination events.
Description
Number of rumination events measured by questionnaires administered daily for 10 days before and after treatment.
Time Frame
4 weeks
Title
Abdominal discomfort.
Description
Abdominal discomfort will be measured by scales graded from 0 (no discomfort) to 10 (severe discomfort) administered daily for 10 days before and after treatment.
Time Frame
4 weeks
Title
Number of self perceived rumination events up to 6 months.
Description
Number of self perceived rumination events measured daily for 10 days using questionnaires at 1 month, 3 months and 6 months after treatment.
Time Frame
up to 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Rumination syndrome
Exclusion Criteria:
Relevant organic diseases
Facility Information:
Facility Name
Vall d'Hebron Research Institute
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
12. IPD Sharing Statement
Learn more about this trial
Treament of Rumination
We'll reach out to this number within 24 hrs